연구동향 분석

Factors Influencing Imatinib-Induced Hepatotoxicity

한지민 이정 조윤숙 곽혜선 2020년

논문상세정보
    • 저자 한지민 이정 조윤숙 곽혜선
    • 제어번호 106509077
    • 학술지명 Cancer Research and Treatment
    • 권호사항 Vol. 52 No. 1 [ 2020 ]
    • 발행처 대한암학회
    • 발행처 URL http://www.cancer.or.kr
    • 자료유형 학술저널
    • 수록면 181-188
    • 언어 English
    • 출판년도 2020
    • 등재정보 KCI등재
    • 소장기관 경북대학교 도서관 의학분관 부산대학교 중앙도서관
    • 판매처
    유사주제 논문( 0)
인용/피인용

' Factors Influencing Imatinib-Induced Hepatotoxicity' 의 참고문헌

  • hOCT 1 and resistance to imatinib
    Crossman LC [2005]
  • Very important pharmacogene summary : ABCB1(MDR1, P-glycoprotein)
    Hodges LM [2011]
  • Specific targeted therapy of chronic myelogenous leukemia with imatinib
  • Recent status of drug-induced liver injury and its problem in japan
    Takikawa H [2010]
  • Proton pump inhibitors in cirrhosis : tradition or evidence based practice
    Lodato F [2008]
  • Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase : S0033
    Blanke CD [2008]
  • Pharmacokinetic resistance to imatinib mesylate : role of the ABC drug pumps ABCG2(BCRP)and ABCB1(MDR1)in the oral bioavailability of imatinib
    Burger H [2004]
  • Pharmacokinetic interaction between ketoconazole and imatinib mesylate(Glivec)in healthy subjects
    Dutreix C [2004]
  • OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib(AMN107) : reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib
    White DL [2006]
  • Interaction of the efflux transporters ABCB1 and ABCG2 with imatinib, nilotinib, and dasatinib
    Eadie LN [2014]
  • Indications for imatinib mesylate therapy and clinical management
    Guilhot F [2004]
  • Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia : a subanalysis of the IRIS study
    Larson RA [2008]
  • Imatinib mesylate(gleevec)hepatotoxicity
  • Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
  • Highlights of prescribing information: Gleevec (imatinib mesylate)
  • Hepatotoxicity of tyrosine kinase inhibitors : clinical and regulatory perspectives
    Shah RR [2013]
  • Effects of concomitant medication use on gefitinib-induced hepatotoxicity
    Cho S [2018]
  • Effect of rifampicin on the pharmacokinetics of imatinib mesylate(Gleevec, STI571)in healthy subjects
    Bolton AE [2004]
  • Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia
    Kong JH [2007]
  • Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
    Haouala A [2011]
  • Drug absorption interactions between oral targeted anticancer agents and PPIs : is pH-dependent solubility the Achilles heel of targeted therapy
    Budha NR [2012]
  • Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1(hOCT1; SLC22A1), hOCT2(SLC22A2), and hOCT3(SLC22A3)
    Bourdet DL [2005]
  • Clinical pharmacokinetics of imatinib
    Peng B [2005]
  • Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients
    Zhuang W [2018]
  • Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
    Cohen MH [2002]
  • Approval summary : imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
    Johnson JR [2003]
  • Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour : a randomised, double-blind, placebo-controlled trial
    Dematteo RP [2009]
  • Active transport of imatinib into and out of cells : implications for drug resistance
    Thomas J [2004]
  • ABC multidrug transporters : structure, function and role in chemoresistance
    Sharom FJ [2008]